Laminar Pharmaceuticals
Next generation medicines!
This information is confidential, do not share or copy.
You can visit their website or
Equity Story Orphan Drug Designation by FDA Orphan Drug Designation by EMA Premio Onda Cero Investigación y Ciencia 2022 Orphan Drug Designation by EMA 2 LAM561 mechanism of action - selected papers 2005-2012 Laminar Technology Platform: Molecular Basis of Melitherapy LAM561 Clinical Efficacy and Safety refports (Clinical Trials in Humans, phases 1A, 1B, 2A)
Under evaluation at least till: 7th June 2019
KEEP REVIEWING